4BASEBIO UK SOCIETAS (4BB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 4BASEBIO UK SOCIETAS (4BB) has a cash flow conversion efficiency ratio of -0.402x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-7.64 Million ≈ $-929.69 USD) by net assets (GBX18.98 Million ≈ $2.31K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4BASEBIO UK SOCIETAS defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
4BASEBIO UK SOCIETAS - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how 4BASEBIO UK SOCIETAS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
4BASEBIO UK SOCIETAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 4BASEBIO UK SOCIETAS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Duros S.A.
AT:DUR
|
-0.182x |
|
Prominence Energy Limited
F:RSX
|
-0.150x |
|
Aranjin Resources Ltd
V:ARJN
|
-0.499x |
|
Wingara AG Ltd
AU:WNR
|
-1.348x |
|
TH1NG AB
ST:TH1NG
|
0.336x |
|
Avation PLC
LSE:AVAP
|
-0.005x |
|
Pathfinder Ventures Inc
V:RV
|
0.233x |
|
River and Mercantile UK Micro Cap Investment Company Ltd
LSE:RMMC
|
-0.007x |
Annual Cash Flow Conversion Efficiency for 4BASEBIO UK SOCIETAS (2019–2024)
The table below shows the annual cash flow conversion efficiency of 4BASEBIO UK SOCIETAS from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see 4BASEBIO UK SOCIETAS market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX26.38 Million ≈ $3.21K |
GBX-10.74 Million ≈ $-1.31K |
-0.407x | -103.24% |
| 2023-12-31 | GBX-492.00K ≈ $-59.86 |
GBX-6.18 Million ≈ $-751.68 |
12.557x | +2000.62% |
| 2022-12-31 | GBX7.12 Million ≈ $866.30 |
GBX-4.70 Million ≈ $-572.34 |
-0.661x | -181.99% |
| 2021-12-31 | GBX11.70 Million ≈ $1.42K |
GBX-2.74 Million ≈ $-333.38 |
-0.234x | -254.37% |
| 2020-12-31 | GBX15.46 Million ≈ $1.88K |
GBX-1.02 Million ≈ $-124.35 |
-0.066x | -146.45% |
| 2019-12-31 | GBX-1.89 Million ≈ $-229.96 |
GBX-269.00K ≈ $-32.73 |
0.142x | -- |
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applicat… Read more